APGE (Apogee Therapeutics) 6-Month Price Index: 1.97 (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APGE Apogee Therapeutics Inc APGE
22 GF Score
Price $135.07
! 3 Warning Signs
View Full Analysis

What is Apogee Therapeutics 6-Month Price Index?

Apogee Therapeutics APGE -0.01% 22 6-Month Price Index is 1.97 as of Sep. 04, 2026. GuruFocus rates APGE with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-04), Apogee Therapeutics's 6-Month Price Index is 1.97.

Apogee Therapeutics  (NAS:APGE) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Apogee Therapeutics 6-Month Price Index Related Terms

APGE vs IONS, KRYS, CYTK: 6-Month Price Index Comparison

For the Biotechnology subindustry, Apogee Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

APGE
22GF Score
Apogee Therapeutics Inc APGE
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apogee Therapeutics  (NAS:APGE) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.97 mean?
Apogee Therapeutics (APGE) has a 6-Month Price Index of 1.97 as of Sep. 04, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Apogee Therapeutics and its competitors.
Is Apogee Therapeutics' 6-Month Price Index too high?
Apogee Therapeutics' current 6-Month Price Index is 1.97. Overall, Apogee Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Apogee Therapeutics' 6-Month Price Index compare to IONS and KRYS?
Apogee Therapeutics' 6-Month Price Index of 1.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Apogee Therapeutics and its competitors. Apogee Therapeutics's current 6-Month Price Index is 1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apogee Therapeutics stock overvalued right now?
Apogee Therapeutics (APGE) has a current 6-Month Price Index of 1.97. The current 6-Month Price Index is 1.97. Apogee Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Apogee Therapeutics (APGE), the current 6-Month Price Index is 1.97 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apogee Therapeutics Business Description

Address 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
22GF Score

Get the complete analysis for APGE

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$135.07
Price